Spots Global Cancer Trial Database for urethral cancer associated with invasive bladder cancer
Every month we try and update this database with for urethral cancer associated with invasive bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | NCT00082719 | Bladder Cancer Urethral Cancer | Recombinant Int... | - | M.D. Anderson Cancer Center | |
| S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | NCT00066612 | Bladder Cancer Transitional Ce... Urethral Cancer | irinotecan hydr... | 18 Years - | SWOG Cancer Research Network | |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | NCT00045630 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin gemcitabine paclitaxel surgery | 18 Years - | SWOG Cancer Research Network | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | NCT01191892 | Bladder Cancer Transitional Ce... Ureter Cancer Urethral Cancer | carboplatin gemcitabine hyd... vandetanib Placebo | 18 Years - 120 Years | Cardiff University | |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | NCT00478361 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | Gemcitabine hyd... Paclitaxel Doxorubicin hyd... Pegfilgrastim | - | M.D. Anderson Cancer Center | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | NCT00003376 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | NCT01611662 | Distal Urethral... Proximal Urethr... Squamous Cell C... Stage II Bladde... Stage III Bladd... Urethral Cancer... | gemcitabine hyd... cisplatin therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | NCT00021099 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | NCT01611662 | Distal Urethral... Proximal Urethr... Squamous Cell C... Stage II Bladde... Stage III Bladd... Urethral Cancer... | gemcitabine hyd... cisplatin therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00083213 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) | NCT01089088 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... sunitinib malat... | 16 Years - 120 Years | Cardiff University | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00006351 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... lonafarnib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | NCT00053209 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | NCT00397488 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer | NCT00022191 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... paclitaxel | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients | NCT00253383 | Cancer | counseling inte... educational int... psychosocial as... quality-of-life... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | NCT00045630 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin gemcitabine paclitaxel surgery | 18 Years - | SWOG Cancer Research Network | |
| Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer | NCT00002684 | Bladder Cancer Urethral Cancer | cisplatin ifosfamide paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract | NCT00006026 | Bladder Cancer Transitional Ce... Urethral Cancer | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | NCT00407485 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Squamous Cell C... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ziv-aflibercept pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract | NCT00006111 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin fluorouracil conventional su... radiation thera... | 18 Years - 70 Years | UNICANCER | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | NCT00004856 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer | NCT01639521 | Anterior Urethr... Localized Trans... Posterior Ureth... Recurrent Bladd... Recurrent Ureth... Regional Transi... Stage III Bladd... Transitional Ce... Ureter Cancer Urethral Cancer... | cisplatin gemcitabine hyd... methotrexate vinblastine doxorubicin hyd... pegfilgrastim laboratory biom... | 18 Years - | University of Southern California | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
